A phase 3, open label, randomized study to compare the efficacy and safety of odronextamab (REGN1979), an anti-CD20 x anti-CD3 bispecific antibody, in combination with lenalidomide versus rituximab in combination with lenalidomide in relapsed/refractory participants with follicular lymphoma and marginal zone lymphoma (OLYMPIA-5)

Ghanem, Riad (Researcher)
Kausche, Lea Elisabeth (Researcher)
Klein, Katharina (Researcher)
Kovacsova, Judita (Researcher)
Krenosz, K. J. (Researcher)
Krivic, Denis (Researcher)
Kühr, Thomas (Researcher)
Lichtenauer, Nina (Researcher)
Piringer, Gudrun (Researcher)
Popp, Henning Detlef (Researcher)
Schneeweiß, Bruno (Researcher)
Schwarz, Heike (Researcher)
Stefan, Alex (Researcher)
Stegemann, Maike (Researcher)
Schmitt, Clemens (PI)

Department of Internal Medicine 3 - Hematology and Internal Oncology

Project: Clinical studies › Clinical Study (Industry project)

Description

Status	Active
Effective start/end date	03.07.2024 → 31.12.2027

Fields of science

302024 Haematology
302055 Oncology

Project Details

Description

Fields of science